Advanced @entity1030 ( @entity1030 ) is a significant cause of morbidity. Treatment options beyond conventional medical therapies are limited to a minority of @entity1 . Lung volume reduction surgery (LVRS) although effective in selected subgroups of @entity1 is not commonly undertaken. Morbidity associated with the procedure has contributed to this low utilisation. In response to this, less invasive bronchoscopic lung volume techniques are being developed to attempt to mitigate some of the risks and costs associated with surgery. Of these, endobronchial valve therapy is the most comprehensively studied although the presence of collateral ventilation in a significant proportion of @entity1 has compromised its widespread utility. Bronchial thermal vapour ablation and lung volume reduction (LVR) coils are not dependent on collateral ventilation. These techniques have shown promise in early clinical trials; ongoing work will establish whether they have a role in the management of advanced @entity1030 . Lung transplantation, although effective in selected @entity1 for @entity1109 and improving survival, is limited by donor organ availability and economic constraint. Reconditioning marginal organs previously declined for transplantation with ex vivo lung perfusion (EVLP) is one potential strategy in improving the utilisation of donor organs. By increasing the donor pool, it is hoped lung transplantation might be more accessible for @entity1 with advanced @entity1030 into the future.

Advanced therapies for XXXX -What's on the horizon? Progress in lung volume reduction and lung transplantation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1109 :: ('MESH:D012678', 'Disease') :: ['palliation of symptoms'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD']
@entity1030 :: (MESH:D029424,Disease) :: ['COPD']
